Kobayashi M， Kawa S， Kobayashi M， et al . Malignant insulinoma presenting a nonfunctioning metastatic liver tumor 14 years after resec-tion of the primary tumor[J]. J Gastroenterol， 1998， 33（6）: 891-894. [2] Delcore R， Friesen SR. Gastrointestinal neuroendocrine tumors[J]. J Am Coll Surg， 1994， 178（2）: 187-211.[3] Liu H， Zhang SZ， Wu YL， et al . Diagnosis and surgical treatment of pancreatic endocrine tumors in 36 patients: a single-center report[J]. Chin Med J， 2007， 120（17）:1487-1490.[4] Eriguchi N， Aoyagi S， Hara M， et al . Insulinoma occurring in asso-ciation with fatty replacement of unknown etiology in the pancreas: report of a case[J]. Surg Today， 2000， 30（10）: 937-941.[5] Hirshberg B， Cochran C， Monica C， et al . Malignant insulinoma Spectrum of unusual clinical features[J]. Cancer， 2005， 104（2）: 264-272.[6] Service FJ， McMahon MM， O''Brien PC， et al . Functioning insulino-ma--incidence， recurrence， and long-term survival of patients: a 60-year study[J]. Mayo Clin Proc， 1991， 66（7）: 711-719.[7] Danforth DN Jr， Gorden P， Brennan MF. Metastatic insulin-secre-ting carcinoma of the pancreas: clinical course and the role of surgery[J]. Surgery， 1984， 96（6）: 1027-1037.[8] Gorden P， Skarulis MC， Roach P， et al . Plasma proinsulin-like com-ponent in insulinoma: a 25-year experience[J]. J Clin Endocrinol Metab， 1995， 80（10）: 2884-2887.[9] Graeme-Cook F， Nardi G， Compton CC. Immunocytochemical stai-ning for human chorionic gonadotropin subunits does not predict ma-lignancy in insulinomas[J]. Am J Clin Pathol， 1990， 93（2）: 273-276.[10] Jonkers YM， Claessen SM， Veltman JA， et al . Molecular parame-ters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status[J]. Cytogenet Genome Res， 2006， 115（3-4）: 289-297.[11] Baldelli R， Ettorre G， Vennarecci G， et al . Malignant insulinoma presenting as metastatic liver tumor. Case report and review of the literature[J]. J Exp Clin Cancer Res， 2007， 26（4）:603-607.[12] Portela-Gomes GM， Stridsberg M， Grimelius L， et al . Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4[J]. Endocr Pathol， 2007， 18（2）: 79-85.[13] Healy ML， Dawson SJ， Murray RM， et al . Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malig-nant insulinoma[J]. Intern Med J， 2007， 37（6）:406-409.[14] Brentjens R， Saltz L. Islet cell tumors of the pancreas: The medical oncologist''s perspective[J]. Surg Clin North Am， 2001， 81（3）: 527-542.[15] Frank M， Klose KJ， Wied M， et al . Combination therapy with oct-reotide and[alpha]-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors[J]. Am J Gastroenterol， 1999， 94（5）: 1381-1387.[16] Bourcier ME， Sherrod A， DiGuardo M， et al . Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab， 2009， 94（9）: 3157-3162.[17] Boukhman MP， Karam JH， Shaver J， et al . Insulinoma: Experience from 1950 to 1995[J]. West J Med，1998， 169（2）: 98-104.[18] Gill GV， Rauf O， MacFarlane IA. Diazoxide treatment for insulino-ma: a national UK survey. Postgrad Med J，1997， 73（864）: 640-641.
